Fulcrum Therapeutics Inc
FULC
Get informed when a big investor buys or sells
+ FollowMarket Cap$200.21M
Close$
$3.02
21.7% downside
Current Fair Value
21.7% downsideOvervalued by 21.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $200.21 Million |
|---|---|
| Enterprise Value | $155.82 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.18 |
| Beta | 2.92 |
| Outstanding Shares | 76,215,000 |
Return
| Return on Equity | -22.84% |
|---|---|
| Return on Assets | -21.95% |
| Return on Invested Capital | -24.99% |
Valuation & Multiples
| P/E Ratio | -3.22 |
|---|---|
| PEG | -45.96 |
| Price to Sales | - |
| Price to Book Ratio | 0.96 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.85 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2490▼ 68.76% |
|---|---|
| Total Calls | 571,000▲ 146.12% |
| Total Puts | 142,200▼ 34.56% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 113.20%▲ 5.45% |
|---|---|
| Total Invested | $550.14M▼ 27.87% |
| Investors Holding | 174▼ 4.00% |
ESG Score
No data
About Fulcrum Therapeutics Inc
73 employeesFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies dru...